Supplementary figure S2



	All adverse event				Infection				Malignancy			
	TNFi	IL-6Ri	CTLA4Ig	JAKi	TNFi	IL-6Ri	CTLA4Ig	JAKi	TNFi	IL-6Ri	CTLA4Ig	JAKi
Incidence rate per 100 Patient-Yr	18.2	9.4	10.3	11.5	1.6	2.1	0	1.6	2.6	1.0	0	1.6
Lower CI	12.0	5.0	4.8	5.6	0.4	0.6	0	0.3	0.9	0.2	0	0.3
Upper CI	27.0	17.5	21.6	22.7	5.9	7.4	0	8.7	7.5	5.7	0	8.7
Patients year	110.2	92.6	55.8	60.2	110.2	92.6	55.8	60.2	110.2	92.6	55.8	60.2
Patients with events	21/246 (8.5%)	9/195 (4.6%)	6/119 (5.0%)	7/127 (5.5%)	2/246 (0.8%)	2/195 (1.0%)	0/119 (0%)	1/127 (0.8%)	3/246 (1.2%)	1/195 (0.5%)	0/119 (0%)	1/127 (0.8%)



	Skin rash				Gastrointestinal symptom				Others			
	TNFi	IL-6Ri	CTLA4Ig	JAKi	TNFi	IL-6Ri	CTLA4Ig	JAKi	TNFi	IL-6Ri	CTLA4Ig	JAKi
Incidence rate per 100 Patient-Yr	11.8	1.0	0	1.6	0	1.0	3.4	3.2	2.5	4.1	6.8	4.8
Lower CI	7.1	0.2	0	0.3	0	0.2	0.9	0.9	0.8	1.6	2.7	1.6
Upper CI	19.4	5.7	0	8.7	0	5.7	12.0	11.2	7.1	10.4	16.9	13.7
Patients year	110.2	92.6	55.8	60.2	110.2	92.6	55.8	60.2	110.2	92.6	55.8	60.2
Patients with events	14/246 (5.7%)	1/195 (0.5%)	0/119 (0%)	1/127 (0.8%)	0/246 (0%)	1/195 (0.5%)	2/119 (1.7%)	2/127 (1.6%)	3/246 (1.2%)	4/195 (2.1%)	4/119 (3.4%)	3/127 (2.4%)